GlassScriptPhysician profile
Summer L Ross
NPI 1699897165
$5,271.77
in general payments reported to CMS, 2019-2025
26 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $644 · 2022: $1,565 · 2023: $1,086 · 2024: $932 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,042 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,042.21 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,884.56 | 2021-2025 | Minimed 780g, Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.68 | 2021-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $360.05 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $261.03 | 2021-2024 | Fasenra |
| Abbott Laboratories | $245.59 | 2023-2024 | Freestyle Libre 3, Freestyle Insulinx |
| Novo Nordisk INC | $213.95 | 2021-2022 | |
| Beta Bionics, INC. | $212.49 | 2023 | Ilet Bionic Pancreas |
| Corcept Therapeutics | $211.34 | 2025 | Korlym |
| Regeneron Healthcare Solutions, INC. | $206.14 | 2022-2025 | Dupixent |
| Insulet Corporation | $146.60 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $119.07 | 2025 | |
| Amgen INC. | $118.09 | 2025 | Tavneos |
| Esperion Therapeutics, INC. | $114.53 | 2021 | |
| Olympus America INC. | $113.49 | 2024 | Single Use Aspiration Needle Na-U200h, Single Use Biliary Balloon Dilator |
| Gilead Sciences, INC. | $109.31 | 2025 | Epclusa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $93.93 | 2024 | |
| Alnylam Pharmaceuticals INC. | $76.46 | 2024 | Onpattro |
| Lilly USA, LLC | $59.24 | 2022 | |
| Coloplast Corp | $41.50 | 2023 | Restorelle |
| Merck Sharp & Dohme LLC | $34.84 | 2022-2023 | Vaxelis, Gardasil 9, M-M-R II |
| Abbvie INC. | $34.19 | 2025 | |
| Sanofi Pasteur INC. | $30.66 | 2024 | |
| Pfizer INC. | $25.34 | 2023 | |
| Edwards Lifesciences Corporation | $19.65 | 2025 | Sapien 3 Ultra Resilia |
| Sequel Med Tech, LLC | $19.37 | 2025 | Twiist |
| Dexcom, INC. | $17.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.